Jefferies initiates Iambic stock with buy rating on AI platform
Jefferies initiated coverage on Iambic Therapeutics (NASDAQ:IAM) with a buy rating and $35.00 price target, citing its AI platform's potential. The firm highlighted early data for IAM1363 and modeled peak sales for its pipeline. The stock is up from $10.17 to $13.38 but below its 52-week high. BofA Securities also initiated coverage with a buy rating and $30.00 target, praising its AI-driven drug discovery.
